Corticosteroids in acute respiratory distress syndrome: a step forward, but more evidence is needed.,The Lancet Respiratory Medicine

当前位置： X-MOL 学术 › Lancet Respir. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Corticosteroids in acute respiratory distress syndrome: a step forward, but more evidence is needed.
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2020-02-07 , DOI: 10.1016/s2213-2600(20)30048-5
Kiran Reddy ₁ , Cecilia O'Kane ₂ , Daniel McAuley ₃

Affiliation

Debate continues about the potential role of corticosteroids as therapy for acute respiratory distress syndrome (ARDS). ^, ^, In The Lancet Respiratory Medicine, Jesús Villar and colleagues report the results from a multicentre, open-label, randomised controlled trial investigating prolonged dexamethasone treatment in patients with established moderate-to-severe ARDS, which adds important new data to this debate. In this study, patients in the dexamethasone group had reduced duration of ventilation and mortality compared with those in the control group; the primary outcome, ventilator-free days at 28 days, was increased by 4·8 days (95% CI 2·57 to 7·03; p<0·0001) and mortality at 60 days after randomisation decreased by 15·3% (−25·9 to −4·9; p=0·0047).

中文翻译：

急性呼吸窘迫综合征中的糖皮质激素：向前迈出了一步，但还需要更多的证据。

关于皮质类固醇作为急性呼吸窘迫综合征（ARDS）疗法的潜在作用的争论仍在继续。^， ^，在柳叶刀呼吸内科，赫苏斯·比利亚尔和他的同事从一个多中心，开放标签的报告结果，随机对照试验研究的患者长期地塞米松治疗既定的中度至重度急性呼吸窘迫综合征，增加了重要的新数据，以本次辩论。在这项研究中，与对照组相比，地塞米松组的通气时间和死亡率均降低了。主要结果（无呼吸机天数在28天时）增加了4·8天（95％CI 2·57至7·03； p <0·0001），随机分组后60天的死亡率降低了15·3％（-25·9至-4·9； p = 0·0047）。

更新日期：2020-03-03

点击分享查看原文

点击收藏

阅读更多本刊最新论文